Aquestive Therapeutics (NASDAQ:AQST) CEO Daniel Barber Sells 25,000 Shares

Aquestive Therapeutics, Inc. (NASDAQ:AQST) CEO Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $4.82, for a total transaction of $120,500.00. Following the transaction, the chief executive officer directly owned 652,317 shares in the company, valued at $3,144,167.94. The trade was a 3.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ:AQST opened at $4.82 on Thursday. Aquestive Therapeutics, Inc. has a 52 week low of $2.93 and a 52 week high of $7.55. The company has a market capitalization of $604.96 million, a PE ratio of -7.42 and a beta of 1.48. The company has a 50 day moving average price of $4.42 and a two-hundred day moving average price of $4.27.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The company had revenue of $13.82 million for the quarter, compared to analyst estimates of $11.42 million. On average, sell-side analysts forecast that Aquestive Therapeutics, Inc. will post -0.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $11.00 price objective on shares of Aquestive Therapeutics in a report on Thursday, September 10th. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Friday, July 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Aquestive Therapeutics has an average rating of “Moderate Buy” and an average target price of $9.17.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Elevation Point Wealth Partners LLC bought a new position in Aquestive Therapeutics during the first quarter worth about $42,000. ADAR1 Capital Management LLC lifted its position in shares of Aquestive Therapeutics by 103.9% in the first quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock valued at $42,000 after buying an additional 264,000 shares during the last quarter. Wealthfront Advisers LLC acquired a new stake in shares of Aquestive Therapeutics in the second quarter valued at approximately $44,000. Legal & General Group Plc bought a new position in shares of Aquestive Therapeutics during the 2nd quarter worth approximately $44,000. Finally, Keating Financial Advisory Services Inc. acquired a new position in shares of Aquestive Therapeutics during the 2nd quarter worth approximately $52,000. 32.45% of the stock is owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines delivered through its PharmFilm technology. The company’s dissolvable oral-film platform is designed to provide alternatives to conventional tablets, capsules and injectable therapies, with potential benefits for patients who have difficulty swallowing or require rapid, convenient administration.

Aquestive’s commercial products include Exservan, an oral film formulation of riluzole for people with amyotrophic lateral sclerosis; Libervant, a buccal film formulation of diazepam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity; and Sympazan, an oral film formulation of clonazepam for the treatment of seizures associated with Lennox-Gastaut syndrome.